Sensi-IP is an investigational medical device. The statements made regarding Sensi-IP have not been reviewed by any regulatory agency, including the US Food and Drug Administration (FDA). Sensi-IP is not currently approved for sale in any geography.
THE SCIENCE OF BETTER SOLUTIONS.
FOR PEOPLE AND PLANET.
A VISION FOR
BETTER LIVING
IR Scientific (IR) was born of a passion for improving lives while reducing the impact on your body and the planet. We specialize in the design and development of disruptive and ready-to-commercialize consumer, industrial, and professional solutions. Our unique inorganic polymer platforms allow us to control a number of important natural variables while delivering valuable elemental payloads with precision—where and when they’re needed.
Our first product, Sensi-IP, is set to reimagine oral care. Our impact on sensitivity relief will provide decades of over-the-counter-dental care products and applications.
​
BESPOKE BIOMATERIALS
WITH INFINITE POSSIBILITIES
Proven safe and effective, our unique biomaterials are suited to a variety of applications in consumer and professional oral health, personal care, and even broad industrial markets and can be tailored to degrade back into its constituent elements to prevent the buildup of non-native materials in the mouth.
SUBSTANTIAL AND
PROVEN BENEFITS
Our uniquely engineered biomaterial platform offers countless benefits to people, the planet, and forward-thinking companies.
BENEFICIAL
PAYLOADS
Carries calcium, magnesium, potassium, fluoride, zinc into the body or nearly any surface.
​
EASY TO MANUFACTURE
The company has identified scalable manufacturing solutions within North America.
​
VARIABLE PARTICLE SIZE & SHAPE
Potential for large, irregular particles for high abrasion, or smooth spheres for gentle scrubbing.
​
CLINICALLY
TESTED
Sensi-IP has been clinically-tested and demonstrated its effectiveness in relief of dentinal hypersensitivity in human subjects.
ENVIRONMENTALLY SOUND
Zero residual material after use,
and lower energy required for production.
​
20+
YEARS
OF
INNOVATION POTENTIAL
Expanded oral care opportunities
IR’s bespoke oral care platform has immediate application in sensitivity relief.
That opportunity is huge and nearly untapped. Direct consumer and industry feedback confirm the oral care market is ripe for disruption, with a proliferation of aging technologies that have little patent protection for key ingredients.
​
Over-the-counter mouthwashes and rinses
POTENTIAL FUTURE APPLICATIONS
OUR TEAM
Our management team is best-in-class, and our directors and advisors are globally recognized experts in their fields.
MANAGEMENT
TEAM
John Boresi
CEO
35+ years dental industry executive experience in manufacturing, commercialization and distribution, including oral care medical devices.
Innovation focused growth agent with experience in opening new markets.
Andrew Doyle
Co-founder, Director, Head of Business Development
IR Scientific CEO from founding to January 2020.
Extensive CPG and retail experience with Coca-Cola, Diageo, P&G, Unilever, Loblaw, Sobeys and more.
​
Partner, Strategic Lead at Exit Science, an exit-focused, data driven business strategy consulting firm
Co-founder and CEO of tech start-up Oris 4.
Peter Hickey
Co-founder, Executive Director
Co-founder, Chairman, Allumiqs Corporation.
Co-founder of Adaptiiv Medical Technologies.
Experience in the financing and leadership of medical device companies through FDA clearance and clinical trials.
Roar Askheim
Chief Financial Officer
Business modelling and transaction specialist.
Key team member on the sale of Ocean Nutrition to DSM.
CFO and key negotiator at Ascenta Health for its sale to Nature’s Way.
DIRECTORS
& ADVISORS
Robin Phillips
Director
​
Dr. Neil Smith
Director
Arjan Chima
Director
Dr. Daniel Boyd
Advisor
Globally recognized leader in biomaterials research.
​Holder or contributor to 200+ patented formulations of biomaterials.
​Co-founder of ABK BioMedical and ClearDynamic.
Peter Saladin
Advisor
Retired Global Head of Diagnostics Licensing with Roche.
Specializes in the structure and terms on global technology licensing and IP acquisition.